BC Week In Review | Apr 20, 2018
Company News

BMS, JNJ in deal for Factor XIa inhibitor

Bristol-Myers Squibb Co. (NYSE:BMY) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize Factor XIa inhibitors, including BMS-986177. BMS will receive an undisclosed upfront payment and is eligible...
BC Extra | Apr 16, 2018
Company News

BMS, JNJ in deal for Factor XIa inhibitor

Bristol-Myers Squibb Co. (NYSE:BMY) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize Factor XIa inhibitors, including BMS-986177. BMS will receive an undisclosed upfront payment and is eligible...
Items per page:
1 - 2 of 2